Can long-term benzodiazepine and zolpidem use cause GABA-A receptor adaptation and tolerance?

Long-term exposure to benzodiazepines—and, with more qualification, zolpidem—can induce adaptations in GABA-A–mediated inhibitory signaling. These adaptations provide a biologically coherent explanation for tolerance and for withdrawal symptoms when treatment is stopped, particularly abruptly.

Clinical and mechanistic evidence

• Benzodiazepines: Animal, cellular, and translational studies support changes in GABA-A receptor expression/subunit composition, receptor trafficking, benzodiazepine–GABA-A coupling, and inhibitory-synapse remodeling during prolonged exposure. These changes can reduce drug responsiveness and “inhibitory reserve,” consistent with pharmacologic tolerance.
• Zolpidem: Experimental continuous exposure has reduced GABA-stimulated benzodiazepine-site binding, supporting GABA-A receptor adaptation. However, clinical tolerance to zolpidem’s hypnotic effect is less consistently demonstrated than with classical benzodiazepines; dependence and withdrawal may occur even when overt tolerance is not clearly established.

Discontinuation and withdrawal

• Removing positive allosteric GABA-A modulation can transiently reveal reduced inhibitory capacity and compensatory excitatory plasticity. Increased glutamatergic/AMPA signaling is a plausible contributor, although this specific pathway is not fully established in humans.
• The resulting central nervous system hyperexcitability is clinically reflected by rebound insomnia, anxiety, tremor, and perceptual symptoms. Rebound insomnia and anxiety after abrupt cessation or large dose reductions are well supported.
• Seizures are a recognized serious withdrawal complication, particularly after abrupt discontinuation, high doses, or substantial long-term exposure.

Bottom line

• The claim is supported with moderate confidence: chronic benzodiazepine use, and plausibly chronic zolpidem use, can produce GABA-A–related neuroadaptation that temporarily dysregulates inhibition after cessation. The clinical implication is that abrupt stopping can be hazardous—especially in an older adult—and discontinuation should generally be medically supervised and individualized.